Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)
2023年7月11日 - 9:00PM
ビジネスワイヤ(英語)
Rallybio Corporation (Nasdaq: RLYB) today announced that an
abstract reporting results from the Phase 1 first-in-human single
ascending dose clinical study of RLYB116 has been accepted for
presentation as a poster at the 29th International Complement
Workshop (ICW), which will take place in Newcastle, UK from August
31 - September 5. RLYB116 is a novel, potentially long-acting
subcutaneously injected inhibitor of C5 in development for the
treatment of patients with complement-mediated diseases.
Details of the poster presentation are as follows:
- Title: Phase 1 clinical data for single-dose
subcutaneous injection of RLYB116, a C5 blocking Affibody® molecule
linked to an Albumod® albumin binding domain
- Presenting Author: Eric Watsky, M.D., Rallybio
- Abstract Number: 36
- Poster Session Date and Time: September 3, 2023, from
14:30 - 16:30 (2:30 p.m. - 4:30 p.m. ET)
Additional information about the ICW 2023 Congress is available
at: https://icw2023newcastle.co.uk/.
About Rallybio
Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology
company with a mission to develop and commercialize
life-transforming therapies for patients with severe and rare
diseases. Rallybio has built a broad pipeline of promising product
candidates aimed at addressing diseases with unmet medical need in
areas of maternal fetal health, complement dysregulation,
hematology, and metabolic disorders. The Company has two clinical
stage programs: RLYB212, an anti-HPA-1a antibody for the prevention
of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and
RLYB116, an inhibitor of complement component 5 (C5), with the
potential to treat several diseases of complement dysregulation, as
well as additional programs in preclinical development.
Rallybio is headquartered in New Haven, Connecticut with an
additional facility at the University of Connecticut’s Technology
Incubation Program in Farmington, Connecticut. For more
information, please visit www.rallybio.com and follow us on
LinkedIn and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are
based on our management’s beliefs and assumptions and on currently
available information. All statements, other than statements of
historical facts contained in this press release are
forward-looking statements. In some cases, forward-looking
statements can be identified by terms such as “may,” “will,”
“should,” “expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negative of these terms
or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements in this
press release include, but are not limited to, statements
concerning results from the Phase 1 first-in-human single ascending
dose clinical study of RLYB116, and statements concerning the
expected progress, results and plans for RLYB116. The
forward-looking statements in this press release are only
predictions and are based largely on management’s current
expectations and projections about future events and financial
trends that management believes may affect Rallybio’s business,
financial condition and results of operations. These
forward-looking statements speak only as of the date of this press
release and are subject to a number of known and unknown risks,
uncertainties and assumptions, including, but not limited to, our
ability to successfully initiate and conduct our planned clinical
studies, and complete such clinical studies and obtain results on
our expected timelines, or at all, whether our cash resources will
be sufficient to fund our operating expenses and capital
expenditure requirements and whether we will be successful raising
additional capital, our ability to enter into strategic
partnerships or other arrangements, competition from other
biotechnology and pharmaceutical companies, and those risks and
uncertainties described in Rallybio’s filings with the U.S.
Securities and Exchange Commission (SEC), including Rallybio’s
Quarterly Report on Form 10-Q for the period ended March 31, 2023,
and subsequent filings with the SEC. The events and circumstances
reflected in our forward-looking statements may not be achieved or
occur and actual future results, levels of activity, performance
and events and circumstances could differ materially from those
projected in the forward-looking statements. Except as required by
applicable law, we are not obligated to publicly update or revise
any forward-looking statements contained in this press release,
whether as a result of any new information, future events, changed
circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230710905244/en/
Investor Contacts Ami Bavishi Head of Investor Relations
and Communications 475-47-RALLY (Ext. 282)
abavishi@rallybio.com
Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200
hannah.deresiewicz@sternir.com
Media Contact Tara DiMilia 908-369-7168
Tara.dimilia@tmstrat.com
Rallybio (NASDAQ:RLYB)
過去 株価チャート
から 4 2024 まで 5 2024
Rallybio (NASDAQ:RLYB)
過去 株価チャート
から 5 2023 まで 5 2024